Does Medicaid cover Wegovy?

There is no single national answer, and anyone who gives you one is guessing. Medicaid is administered state by state, and coverage of medicines for weight management is one of the areas where states differ most.

Why there is no national answer

Medicaid is a joint federal and state programme. Within federal rules, states set a great deal of their own policy, including which drugs they cover, on what terms, and with what prior authorisation requirements.

That means the answer for Texas is not the answer for New York, and the answer this year may not be the answer next year.

How to find your actual answer

Three places, in this order.

1. Your state Medicaid agency's preferred drug list. Every state publishes one. Search for your state's name plus "Medicaid preferred drug list" and look for the weight management or endocrine section.

2. Your managed care plan, if you have one. Many people on Medicaid are enrolled in a managed care organisation which administers the drug benefit. The number on your card is the fastest route.

3. Your prescriber's office. They deal with your state's prior authorisation process routinely and will usually know the current position.

Ask specifically: is the medicine covered for chronic weight management, and what does prior authorisation require?

The brand distinction matters here too

Wegovy and Zepbound are the weight management brands. Ozempic and Mounjaro are the type 2 diabetes brands of the same two molecules.

State Medicaid programmes have generally covered diabetes medicines. Weight management is the area where coverage varies. So if you have type 2 diabetes, the coverage conversation is a different one from the one on this page.

What changes from 2027

This is the part worth knowing in advance.

CMS has created a model called BALANCE, and state Medicaid agencies can choose to join it. Under BALANCE, CMS negotiates GLP-1 pricing and coverage terms with manufacturers on behalf of participating state Medicaid agencies and Medicare Part D plans.

States could join from May 2026 through 1 January 2027. The model pairs medication access with lifestyle support covering reduced calorie diet and increased physical activity.

Participation is voluntary. So this does not create national Medicaid coverage. It creates a mechanism a state can opt into, which means the state by state variation continues, on a different basis.

The practical implication: if your state does not cover these medicines today, it is worth asking whether it has joined BALANCE, because that could change the answer for 2027.

If Medicaid does not cover it

The other routes still exist.

If you are dually eligible for Medicare and enrolled in Part D, the Medicare GLP-1 Bridge provides certain GLP-1 drugs at fifty dollars a month through 31 December 2027.

If you are paying cash, the federal TrumpRx.gov prices launched in February 2026 are well below 2025 list prices, though you need a prescription you already hold.

What to ask

• Is this medicine on my state's preferred drug list for weight management?
• What does prior authorisation require in my state?
• Am I in a managed care plan, and does it apply different rules?
• Has my state joined the BALANCE model for 2027?
• If I have type 2 diabetes, does the diabetes indication change the answer?

Sources

• Medicaid.gov, prescription drug benefit and state flexibility
• Centers for Medicare and Medicaid Services, BALANCE Model and Request for Applications
• Centers for Medicare and Medicaid Services, Medicare GLP-1 Bridge
• The White House, Fact Sheet on the launch of TrumpRx.gov, 6 February 2026

How we verify: see /how-we-verify.

Keep reading

All four ways to pay compared, at /guides/how-to-pay-for-glp1.

How to work a prior authorisation and an appeal, at /guides/get-glp1-covered-by-insurance.